Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × belzutifan × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Renal Cell 21 Kidney Neoplasms 8 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 von Hippel-Lindau Disease 4 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

pembrolizumab 150 Gemcitabine 135 Paclitaxel 128 Carboplatin 118 Bevacizumab 110 Surveys and Questionnaires 97 Docetaxel 95 Cisplatin 94 Cyclophosphamide 93 Exercise 89 Blood Specimen Collection 85 Nivolumab 82 Fluorouracil 75 Capecitabine 73 Dexamethasone 70 Radiotherapy 69 Irinotecan 62 Standard of Care 59 Pemetrexed 59 Oxaliplatin 57 Leucovorin 54 Drug Therapy 54 Cetuximab 48 Erlotinib Hydrochloride 46 atezolizumab 44 Sorafenib 44 Interviews as Topic 41 Doxorubicin 41 Ipilimumab 38 Magnetic Resonance Spectroscopy 37

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04976634 2025-04-06

MK-6482-016

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡